WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 206711

CAS#: None

Description: ONC1-13B is an antagonist of androgen receptor, with similar to MDV3100 and ARN-509 mechanism of action. ONC1-13B efficiently inhibits DHT-stimulated PSA expression and proliferation of prostate cancer cells, prevents binding of androgens to the AR ligand-binding domain, androgen-stimulated AR nuclear translocation and coactivator complex formation. In the LnCaP-Z2 xenograft model of prostate cancer ONC1-13B inhibits tumor growth and suppresses PSA expression. Thus ONC1-13B is a new promising antiandrogen demonstrating high efficacy in a preclinical model of prostate cancer, with lower potential for seizures and drug-drug interaction.

Chemical Structure

CAS# None

Theoretical Analysis

MedKoo Cat#: 206711
Name: ONC1-13B
CAS#: None
Chemical Formula: C22H16F4N4O3S
Exact Mass: 492.0879
Molecular Weight: 492.4486
Elemental Analysis: C, 53.66; H, 3.28; F, 15.43; N, 11.38; O, 9.75; S, 6.51

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: ONC1-13B; ONC113B; ONC 113B; ONC1-0013B; ONC 10013B; ONC-10013B.

IUPAC/Chemical Name: (R)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-4-oxo-2-thioxo-7-oxa-1,3-diazaspiro[4.4]nonan-1-yl)-2-fluoro-N-methylbenzamide


InChi Code: InChI=1S/C22H16F4N4O3S/c1-28-18(31)15-5-4-14(9-17(15)23)30-20(34)29(19(32)21(30)6-7-33-11-21)13-3-2-12(10-27)16(8-13)22(24,25)26/h2-5,8-9H,6-7,11H2,1H3,(H,28,31)/t21-/m1/s1

SMILES Code: FC1=C(C(NC)=O)C=CC(N2[C@@]3(CCOC3)C(N(C4=CC(C(F)(F)F)=C(C#N)C=C4)C2=S)=O)=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 492.4486 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Ivachtchenko AV, Ivanenkov YA, Mitkin OD, Vorobiev AA, Kuznetsova IV, Shevkun
NA, Koryakova AG, Karapetian RN, Trifelenkov AS, Kravchenko DV, Veselov MS,
Chufarova NV. Design, synthesis and biological evaluation of novel
5-oxo-2-thioxoimidazolidine derivatives as potent androgen receptor antagonists.
Eur J Med Chem. 2015 Jun 24;99:51-66. doi: 10.1016/j.ejmech.2015.05.039. Epub
2015 Jun 2. PubMed PMID: 26046313.

2: Ivachtchenko AV, Mitkin OD, Kudan EV, Rjahovsky AA, Vorobiev AA, Trifelenkov
AS, Shevkun NA, Proskurina OV, Kravchenko DV, Karapetian RN. Preclinical
Development of ONC1-13B, Novel Antiandrogen for Prostate Cancer Treatment. J
Cancer. 2014 Jan 21;5(2):133-42. doi: 10.7150/jca.7773. eCollection 2014. PubMed
PMID: 24494031; PubMed Central PMCID: PMC3909768.